Loading stock data…
$7.90-0.64 (-7.49%)
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.
Akari Therapeutics, Plc in the Healthcare sector is trading at $7.90 with a market capitalization of $22M. Wall Street consensus targets $25.50 (3 analysts), implying a +222.8% move over the next 12 months. The stock is currently near its 52-week low of $3.02, remaining 14.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.60M↓ | -$3.63M↓ | -$3.23M↓ | -$2.22M↑ | -$3.12M |
| Net Income | -$4.81M↑ | -$14.46M↓ | -$5.30M↑ | -$6.40M↓ | -$1.90M |
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell ki...